Iranian Journal of Immunology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Journal Metrics

Implications of Complement Imbalance in COVID-19: A Molecular Mechanistic Discussion on the Importance of Complement Balance

Document Type : Review Article

Authors

1 Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Department of Microbiology, Sciences, and Research Branch, Islamic Azad University, Fars, Iran.

3 Université Victor Segalen Bordeaux 2, France.

4 Department of Biology, Dezful Branch, Islamic Azad University, Dezful, Iran.

5 Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Two central questions in COVID-19 treatment which should be considered are: “How does the imbalance of the complement system affect the therapeutic approaches?” and “Do we consider complement inhibitors in therapeutic protocols?”. The complement system is a double-edged sword since it may either promote immune responses against COVID-19 or contribute to destructive inflammation in the host. Therefore, it is crucial to regulate this system with complement inhibitors. In this manuscript, we discuss the molecular mechanisms of complement and complement inhibitors in COVID-19 patients. We searched the terms “COVID-19”, “Complement”, “Complement inhibitor”, “SARS-CoV-2”, and all complement fragments and inhibitors from 2000 to 2022 in PubMed and google scholar and checked the pathways in “KEGG pathway database”. Complement is not well-appreciated in the treatment protocols despite its multiple roles in the disease, and most of the preventive anti-inflammatory therapeutic approaches did not include a complement inhibitor in COVID-19 therapeutic protocols. In this review article, we discussed the most recent studies regarding complement components mediated interventions and the mechanism of these interventions in COVID-19 patients. Since the control of the complement system overactivation is associated with a better prognosis in the initial stages of COVID-19, heparin, anti-thrombin, C1-inhibitor, montelukast, and hydralazine can be effective in the initial stages of this viral infection. Recombinant complement activation (RCA) proteins are more effective in regulating complement compared to terminal pathway therapeutic approaches such as the C3a and C5a inhibitors.

Keywords

References
  1. Nepal B. Coping with COVID-19. Journal of Lumbini Medical College. 2020;8(1):1-2.
  2. Helfrich B. The Ethical Justification of Research in Pediatric Healthcare with an Emphasis on the COVID-19 Vaccine. 2022.
  3. Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Molecular Biology Reports. 2021:1-12.
  4. Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. 2020.
  5. Stravalaci M, Pagani I, Paraboschi EM, Pedotti M, Doni A, Scavello F, et al. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nat Immunol. 2022;23(2):275-86.
  6. Malaquias MAS, Gadotti AC, da Silva Motta-Junior J, Martins APC, Azevedo MLV, Benevides APK, et al. The role of the lectin pathway of the complement system in SARS-CoV-2 lung injury. Translational Research. 2021;231:55-63.
  7. Satyam A, Tsokos MG, Brook OR, Hecht JL, Moulton VR, Tsokos GC. Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. Clinical Immunology. 2021:108716.
  8. Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood, The Journal of the American Society of Hematology. 2020;136(18):2080-9.
  9. Polycarpou A, Grigoriadou S, Klavinskis L, Sacks S. Does the Lectin Complement Pathway Link Kawasaki Disease and SARS-CoV-2? Frontiers in Immunology. 2020;11.
  10. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. New England Journal of Medicine. 2000;343(15):1064-9.
  11. Edsbäcker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Annals of Allergy, Asthma & Immunology. 2002;88(6):609-16.
  12. Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse P-R, Fobker M, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2021;24(1):145-57.
  13. De Gage SB, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Weill A, et al. Intravitreal Anti–Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic. JAMA ophthalmology. 2021;139(2):240-2.
  14. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology. 2010;215(1):1-11.
  15. Harboe M, Garred P, Karlstrøm E, Lindstad JK, Stahl GL, Mollnes TE. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Molecular immunology. 2009;47(2-3):373-80.
  16. Lachmann PJ. The amplification loop of the complement pathways. Advances in immunology. 2009;104:115-49.
  17. Kilpatrick D, McLintock L, Allan E, Copland M, Fujita T, Jordanides N, et al. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clinical & Experimental Immunology. 2003;134(2):279-84.
  18. Gupta A, Gupta G. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Molecular and Cellular Biochemistry. 2021;476(8):2917-42.
  19. Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, et al. Rationale for targeting complement in COVID‐19. EMBO molecular medicine. 2020;12(8):e12642.
  20. Goya T, Morisaki T, Torisu M. Immunologic assessment of host defense impairment in patients with septic multiple organ failure: relationship between complement activation and changes in neutrophil function. Surgery. 1994;115(2):145-55.
  21. Satyam A, Tsokos GC. Curb complement to cure COVID-19. Clin Immunol. 2020;221:108603.
  22. Elvington M, Scheiber M, Yang X, Lyons K, Jacqmin D, Wadsworth C, et al. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell reports. 2014;8(3):818-30.
  23. Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5).
  24. Lage SL, Rocco JM, Laidlaw E, Rupert A, Galindo F, Kellogg A, et al. Activation of complement components on circulating blood monocytes from COVID-19 patients. Frontiers in Immunology. 2022;13.
  25. Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. Journal of Molecular and Cellular Cardiology. 2022;164:69-82.
  26. Otifi HM, Adiga BK. Endothelial dysfunction in Covid-19. The American Journal of the Medical Sciences. 2022.
  27. Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. International reviews of immunology. 2022;41(2):217-30.
  28. Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proceedings of the National Academy of Sciences. 2020;117(40):25018-25.
  29. Yan B, Freiwald T, Chauss D, Wang L, West E, Mirabelli C, et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science Immunology. 2021;6(58).
  30. Asteris PG, Gavriilaki E, Touloumenidou T, Koravou EE, Koutra M, Papayanni PG, et al. Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks. Journal of cellular and molecular medicine. 2022;26(5):1445-55.
  31. Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. 2006;444(7116):217-20.
  32. Hammerschmidt D, Hudson L, Weaver LJ, Craddock P, Jacob H. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome: pathophysiological relevance and possible prognostic value. The Lancet. 1980;315(8175):947-9.
  33. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translational Research. 2020;220:1-13.
  34. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM. Comparative anti‐inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. British journal of pharmacology. 2004;142(4):756-64.
  35. Canzano P, Brambilla M, Porro B, Cosentino N, Tortorici E, Vicini S, et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. Basic to Translational Science. 2021;6(3):202-18.
  36. Wu M, Jia B-b, Li M-f. Complement C3 and Activated Fragment C3a Are Involved in Complement Activation and Anti-Bacterial Immunity. Frontiers in immunology. 2022;13.
  37. Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. The Journal of Immunology. 2015;194(8):3542-8.
  38. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-γ activation as an anti-inflammatory therapy for respiratory virus infections. Viral immunology. 2010;23(4):343-52.
  39. Mogilenko DA, Danko K, Larionova EE, Shavva VS, Kudriavtsev IV, Nekrasova EV, et al. Differentiation of human macrophages with anaphylatoxin C3a impairs alternative M2 polarization and decreases lipopolysaccharide‐induced cytokine secretion. Immunology and Cell Biology. 2022;100(3):186-204.
  40. Chung JY, Hong J, Kim H-J, Song Y, Yong S-B, Lee J, et al. White adipocyte-targeted dual gene silencing of FABP4/5 for anti-obesity, anti-inflammation and reversal of insulin resistance: Efficacy and comparison of administration routes. Biomaterials. 2021;279:121209.
  41. Xie Y, Feng S-L, Mai C-T, Zheng Y-F, Wang H, Liu Z-Q, et al. Suppression of up-regulated LXRα by silybin ameliorates experimental rheumatoid arthritis and abnormal lipid metabolism. Phytomedicine. 2021;80:153339.
  42. Li Z-F, Wang Y-C, Feng Q-R, Zhuang Y-F, Xie Z-X. Inhibition of the C3a receptor attenuates sepsis-induced acute lung injury by suppressing pyroptosis of the pulmonary vascular endothelial cells. Free Radical Biology and Medicine. 2022;184:208-17.
  43. Shu C, Zha H, Long H, Wang X, Yang F, Gao J, et al. C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts. Journal of Experimental & Clinical Cancer Research. 2020;39(1):1-14.
  44. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nature Reviews Immunology. 2020;20(6):343-4.
  45. Ip WE, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. The Journal of infectious diseases. 2005;191(10):1697-704.
  46. Russkamp NF, Ruemmler R, Roewe J, Moore BB, Ward PA, Bosmann M. Experimental design of complement component 5a‐induced acute lung injury (C5a‐ALI): a role of CC‐chemokine receptor type 5 during immune activation by anaphylatoxin. The FASEB Journal. 2015;29(9):3762-72.
  47. Fattahi F, Kalbitz M, Malan EA, Abe E, Jajou L, Huber‐Lang MS, et al. Complement‐induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction. The FASEB Journal. 2017;31(9):4129-39.
  48. Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine & growth factor reviews. 2021;58:75-81.
  49. Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Molecular Biology Reports. 2021;48(3):2917-28.
  50. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. The Journal of Immunology. 2006;177(7):4794-802.
  51. De Leeuw E, Van Damme KF, Declercq J, Bosteels C, Maes B, Tavernier SJ, et al. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with Covid-19: an open-label randomized controlled trial. 2022.
  52. Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Annals of hematology. 2022;101(2):251-63.
  53. Jima DD, Skaar DA, Planchart A, Motsinger-Reif A, Cevik SE, Park SS, et al. Genomic map of candidate human imprint control regions: the imprintome. Epigenetics. 2022:1-24.
  54. Alis C, Emre DH, Karaali Savrun F, Gunduz A, Uzun Adatepe N. A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment. Neurological Sciences. 2022:1-3.
  55. Burwick RM, Dellapiana G, Newman RA, Smithson SD, Naqvi M, WILLIAMS III J, et al. Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series. American Journal of Reproductive Immunology. 2022.
  56. Karnaukhova E. C1-inhibitor: structure, functional diversity and therapeutic development. Current Medicinal Chemistry. 2022;29(3):467-88.
  57. Kozarcanin H, Lood C, Munthe‐Fog L, Sandholm K, Hamad OA, Bengtsson AA, et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. Journal of Thrombosis and Haemostasis. 2016;14(3):531-45.
  58. Urwyler P, Moser S, Charitos P, Heijnen IA, Rudin M, Sommer G, et al. Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and kallikrein-kinin system. Frontiers in Immunology. 2020;11:2072.
  59. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nature Medicine. 2022;28(1):39-50.
  60. Collaborative QH. I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients. 2020.
  61. Janssen BJ, Halff EF, Lambris JD, Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. Journal of Biological Chemistry. 2007;282(40):29241-7.
  62. Logue GL. Effect of heparin on complement activation and lysis of paroxysmal nocturnal hemoglobinuria (PNH) red cells. 1977.
  63. White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D, et al. Heparin resistance in COVID-19 patients in the intensive care unit. Journal of thrombosis and thrombolysis. 2020;50:287-91.
  64. Tintinger GR, Feldman C, Theron AJ, Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? TheScientificWorldJournal. 2010;10:2403-13.
  65. Khan S, Lynch N. Efficacy of montelukast as added therapy in patients with chronic idiopathic urticaria. Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued). 2012;11(3):235-43.
  66. Silasi‐Mansat R, Zhu H, Georgescu C, Popescu N, Keshari RS, Peer G, et al. Complement inhibition decreases early fibrogenic events in the lung of septic baboons. Journal of cellular and molecular medicine. 2015;19(11):2549-63.
  67. Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology. 2020;215:108450.
  68. Mastellos DC, da Silva BGP, Fonseca BA, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology. 2020;220:108598.
  69. Fang S, Wang H, Lu L, Jia Y, Xia Z. Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study. International immunopharmacology. 2020;89:107070.
  70. Jiang H, Chen Q, Zheng S, Guo C, Luo J, Wang H, et al. Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19. International Journal of General Medicine. 2022;15:849.
  71. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology. 2018;18(1):5.
  72. Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Advances. 2021;5(5):1504-12.
  73. Harkin D, Marron C, Rother R, Romaschin A, Rubin B, Lindsay T. C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm. British journal of surgery. 2005;92(10):1227-34.
  74. de Latour RP, Bergeron A, Lengline E, Dupont T, Marchal A, Galicier L, et al. Complement C5 inhibition in patients with COVID-19-a promising target? Haematologica. 2020;105(12).
  75. Raghunandan S, Josephson CD, Verkerke H, Linam WM, Ingram TC, Zerra PE, et al. Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome. Frontiers in Pediatrics. 2020;8:895.
  76. Sim E, Gill E, Sim R. Drugs that induce systemic lupus erythematosus inhibit complement component C4. The Lancet. 1984;324(8400):422-4.
  77. Schifferli JA. Hydralazine and isoniazid reduce the formation of soluble immune complexes by complement. Immunology letters. 1985;9(5):297-9.
  78. Smith MD, Smith JC. Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to theSARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface.
  79. Rosenthal AR, Self TH, Baker ED, Linden RA. Interaction of isoniazid and warfarin. JAMA. 1977;238(20):2177-.
  80. Krumdieck R, Shaw DR, Huang ST, Poon M-C, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia. The American journal of medicine. 1991;90(1):639-45.
  81. Pérez‐Alós L, Bayarri‐Olmos R, Skjoedt MO, Garred P. Combining MAP‐1: CD35 or MAP‐1: CD55 fusion proteins with pattern‐recognition molecules as novel targeted modulators of the complement cascade. The FASEB Journal. 2019;33(11):12723-34.
  82. Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. The Journal of Immunology. 2000;164(9):4742-51.
  83. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, et al. A new map of glycosaminoglycan and C3b binding sites on factor H. The Journal of Immunology. 2008;181(4):2610-9.
  84. Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19). Clinical & translational immunology. 2020;9(10):e1198.
  85. Jodele S, Köhl J. Tackling COVID‐19 infection through complement‐targeted immunotherapy. British Journal of Pharmacology. 2020.
  86. Woodruff TM, Shukla AK. The complement C5a-C5aR1 GPCR axis in COVID-19 therapeutics. Trends in immunology. 2020.
  87. Carvelli J, Meziani F, Dellamonica J, Cordier PY, Allardet-Servent J, Fraisse M, et al. Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]). Crit Care Med. 2022;50(12):1788-98.
  88. Mansour E, Bueno FF, de Lima-Júnior JC, Palma A, Monfort-Pires M, Bombassaro B, et al. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials. 2021;22(1):1-13.
  89. Graber MA, Wilbur JK. Allergy and Immunology. Family Practice Examination & Board.168.
  90. Rambaldi A, Gritti G, Micò MC, Frigeni M, Borleri G, Salvi A, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020;225(6):152001.
  91. Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clinical Immunology. 2020;219:108555.
  92. Declercq J, Bosteels C, Van Damme K, De Leeuw E, Maes B, Vandecauter A, et al. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):1-3.
Iranian Journal of Immunology
Volume 20, Issue 3
September 2023
Pages 247-261
Files
Share
How to cite
Statistics